<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513483415</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513483415</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Functional −141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter and schizophrenia in a Chinese Han population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Xiao</surname><given-names>Ling</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513483415">1</xref>
<xref ref-type="fn" rid="fn1-0300060513483415">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shen</surname><given-names>Ting</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513483415">2</xref>
<xref ref-type="fn" rid="fn1-0300060513483415">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peng</surname><given-names>Dai-hui</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513483415">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shu</surname><given-names>Chang</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513483415">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jiang</surname><given-names>Kai-da</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513483415">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Gao-hua</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513483415">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513483415"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513483415"><label>1</label>Renmin Hospital of Wuhan University, Wuhan, China</aff>
<aff id="aff2-0300060513483415"><label>2</label>Shanghai Mental Health Centre, Shanghai Jiaotong University, Shanghai, China</aff>
<author-notes>
<fn fn-type="equal" id="fn1-0300060513483415"><label>*</label><p>These authors contributed equally to this work.</p></fn>
<corresp id="corresp1-0300060513483415">Dr Gao-hua Wang, Department of Psychiatry, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang, Wuhan, Hubei 430060, China. Email: <email>wanggaohuad@tom.com</email> or <email>athena7851@yahoo.com.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>1171</fpage>
<lpage>1178</lpage>
<history>
<date date-type="received"><day>28</day><month>1</month><year>2013</year></date>
<date date-type="accepted"><day>15</day><month>2</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec13-0300060513483415"><title>Objective</title>
<p>The association between a putative functional promoter polymorphism, −141C insertion/deletion (Ins/Del), in the dopamine receptor D2 gene (<italic>DRD2</italic>) and schizophrenia was investigated in a Chinese Han population.</p>
</sec>
<sec id="sec14-0300060513483415"><title>Methods</title>
<p>The polymorphism was studied in unrelated schizophrenia patients and unrelated healthy controls. Linkage relationships were explored in core families of the schizophrenic patients using the transmission disequilibrium test. The Positive and Negative Syndrome Scale was used to evaluate the severity of the disorder.</p>
</sec>
<sec id="sec15-0300060513483415"><title>Results</title>
<p>The Del allele was significantly less frequently found in patients (13/120; 11%) than in controls (18/100; 18%). In the 32 core families studied, 16 parents were Ins/Del heterozygotes. Parents transmitted the Ins and Del alleles to their children in 10 and six cases, respectively. Data from core families did not demonstrate linkage. Age, age at onset of schizophrenia and sex were not significantly different between carriers of the Ins and Del alleles. The group with the Ins allele had a significantly higher positive symptom score (75.3 ± 23.4 versus 53.9 ± 21.9) and excitement score (83.6 ± 16.8 versus 50.3 ± 24.6) than the Del group. Groups did not differ significantly in negative symptom and general psychopathology scores.</p>
</sec>
<sec id="sec16-0300060513483415"><title>Conclusions</title>
<p>The <italic>DRD2</italic> −141C Ins/Del polymorphism may affect susceptibility to schizophrenia in a Chinese Han population.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Schizophrenia</kwd>
<kwd>dopamine D2 receptor gene</kwd>
<kwd>polymorphism</kwd>
<kwd>Positive and Negative Syndrome Scale</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513483415" sec-type="intro"><title>Introduction</title>
<p>Schizophrenia is a complex genetic disorder that affects ∼1% of the global population.<sup><xref ref-type="bibr" rid="bibr1-0300060513483415">1</xref>,<xref ref-type="bibr" rid="bibr2-0300060513483415">2</xref></sup> Despite extensive research efforts for many years, no mutations or disease‐predisposing DNA sequence variations for schizophrenia have been identified.<sup><xref ref-type="bibr" rid="bibr3-0300060513483415">3</xref>,<xref ref-type="bibr" rid="bibr4-0300060513483415">4</xref></sup> The mode of inheritance of schizophrenia is likely to be polygenic and multifactorial,<sup><xref ref-type="bibr" rid="bibr5-0300060513483415">5</xref></sup> and association studies are the most important strategies for investigating candidate genes that may be implicated in this disorder. Although the biological basis of schizophrenia is unknown, dopamine is considered to be the main neurotransmitter involved, and genes involved in dopaminergic pathways are being studied as candidate genes for schizophrenia.<sup><xref ref-type="bibr" rid="bibr6-0300060513483415">6</xref></sup> Five distinct subtypes of G‐protein‐coupled dopamine receptors mediate the actions of dopamine, three of which belong to the dopamine D2 family: the dopamine D2 receptor (DRD2), the dopamine D3 receptor (DRD3) and the dopamine D4 receptor (DRD4).<sup><xref ref-type="bibr" rid="bibr7-0300060513483415">7</xref></sup> DRD2 is expressed in the limbic and caudate areas of the brain, and is a target of antipsychotic agents.<sup><xref ref-type="bibr" rid="bibr6-0300060513483415">6</xref></sup> Family, twin and adoption studies suggest that genetic factors play a role in the aetiology of schizophrenia.<sup><xref ref-type="bibr" rid="bibr1-0300060513483415">1</xref></sup> However, no specific hereditary mechanisms have yet been identified for the disease.</p>
<p>Alterations in dopamine transmission and dopamine receptors have been hypothesized in the pathophysiology of schizophrenia.<sup><xref ref-type="bibr" rid="bibr8-0300060513483415">8</xref>,<xref ref-type="bibr" rid="bibr9-0300060513483415">9</xref></sup> Findings from postmortem positron emission tomography studies, although controversial, have highlighted the possibility that DRD2 is linked to the pathophysiology of schizophrenia.<sup><xref ref-type="bibr" rid="bibr10-0300060513483415">10</xref>,<xref ref-type="bibr" rid="bibr11-0300060513483415">11</xref></sup> As DRD2 is a target of antipsychotic drug therapy, its gene (<italic>DRD2</italic>) – which is located on chromosome 11q22–q23 – is a candidate susceptibility gene for schizophrenia.<sup><xref ref-type="bibr" rid="bibr12-0300060513483415">12</xref></sup> In fact, <italic>DRD2</italic> has been proposed as a candidate gene in schizophrenia on both functional and positional grounds.<sup><xref ref-type="bibr" rid="bibr13-0300060513483415">13</xref></sup> An association was reported between a common promoter <italic>DRD2</italic> polymorphism (−141C insert/delete [Ins/Del]) and schizophrenia in a Japanese study.<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> The different alleles in this polymorphism have been shown to differ with regard to in vitro luciferase activity in Y‐79 and 293 cells, indicating that the −141C Ins/Del polymorphism is of functional importance.<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> There has been no replication of this study in a Chinese Han population, however.</p>
</sec>
<sec id="sec2-0300060513483415" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513483415" sec-type="subjects"><title>Participants</title>
<p>Patients and controls taking part in this study were unrelated Han Chinese people. After being provided with a complete description of the study, written consent was obtained from all participants before examination. The study protocol was approved by the Medical Ethics Committee of Renmin Hospital of Wuhan University.</p>
<sec id="sec4-0300060513483415" sec-type="subjects"><title>Patients</title>
<p>All patients included in the study were diagnosed with schizophrenia, using the DSM‐IV‐TR diagnostic criteria.<sup><xref ref-type="bibr" rid="bibr15-0300060513483415">15</xref></sup> Evaluations were undertaken by treating psychiatrists in the Department of Psychiatry, Renmin Hospital of Wuhan University, over a 2-year period between January 2007 and December 2008. Patients were also evaluated regarding the following: age at first hospitalization; abuse of alcohol, solvents or drugs; previous suicide attempts; whether there was a history of schizophrenia spectrum disorders in first‐degree relatives; response to neuroleptic drug treatment; extrapyramidal side-effects; treatment with anticholinergic drugs. Only patients fulfilling a DSM‐IV‐TR diagnosis of schizophrenia were included. All patient interviews and diagnostic assessments were conducted by one of the authors (L. X.).</p>
<p>The Positive and Negative Syndrome Scale (PANSS)<sup><xref ref-type="bibr" rid="bibr16-0300060513483415">16</xref></sup> was chosen to evaluate the severity of schizophrenia because it gives equal weight to positive and negative symptoms. PANSS is a 30‐item scale (total score, 210) comprising subscales for positive and negative symptoms, and general psychopathology. Many studies<sup><xref ref-type="bibr" rid="bibr17-0300060513483415">17</xref><xref ref-type="bibr" rid="bibr18-0300060513483415"/>–<xref ref-type="bibr" rid="bibr19-0300060513483415">19</xref></sup> have analysed PANSS scores and identified five dimensions to the score: negative symptoms; positive symptoms; disorganized thought; uncontrolled hostility/excitement; anxiety/depression. Two of the authors, both of whom are psychiatrists (L. X. and C. S.), were trained in the application of the PANSS by the use of videotaped patient interviews; both trained authors read its Chinese translation, and their performance was confirmed by the assessment of three additional patient interviews. The agreement of scores (Cohen’s κ) between the interviewers was ≥0.80.</p>
</sec>
<sec id="sec5-0300060513483415"><title>Controls</title>
<p>Healthy volunteers, whose geographical region of residence matched that of the patients, were recruited from the general population as control subjects. The control group did not include any people with a positive personal or familial history of major psychiatric disorders.</p>
</sec>
<sec id="sec6-0300060513483415"><title>Families</title>
<p>Linkage relationships were explored in core families of the patients with schizophrenia, using the transmission disequilibrium test (TDT, discussed below).</p>
</sec>
</sec>
<sec id="sec7-0300060513483415"><title>DNA analysis</title>
<p>A 3–5-ml venous blood sample was collected from each participant after informed consent was obtained. Blood was collected into tubes containing 20 g/l ethylenediamine tetra-acetic acid; genomic DNA was extracted from peripheral leucocytes using a genomic DNA isolation kit (Sangon Biological Engineering Technology, Shanghai, China). A total of 284  bp of the 59‐flanking region of the D2 receptor gene was amplified in vitro by means of polymerase chain reaction (PCR) analysis (QIAamp DNA blood mini kit; Qiagen, Valencia, CA, USA), using the primers D2–677 (5′‐ACTGGCGAGCAGACGGTGAGGACCC‐3′) and D2–676 (5′‐TGCGCGCGTGAGGCTGCCGGTTCGG‐3′). Target sequences were amplified in 25 µl of reaction solution. After initial denaturation of the DNA templates for 5 min at 95℃, 32 cycles were performed, each cycle comprised of 94℃ for 1 min, 57℃ for 45 s and 72℃ for 45 s. After the last cycle, samples were incubated at 72℃ for 10 min. The PCR product was digested at 37℃ for 2 h with BstNI (New England Biolabs, Ipswich, MA, USA).The fragments were subjected to electrophoresis on 8% agarose gel, then visualized under ultraviolet light after staining with ethidium bromide.</p>
</sec>
<sec id="sec8-0300060513483415"><title>Statistical analyses</title>
<p>Data were analysed statistically using SPSS® software, version 14.0 (SPSS, Chicago, IL, USA). The statistical significance of differences in genotype distribution and allele frequency between patients and controls was assessed using the χ<sup>2</sup>-test. Overall allele and genotype distributions for each single-nucleotide polymorphism in patients and controls were compared using the GENEPOP program (available at <ext-link ext-link-type="uri" xlink:href="http://wbiomed.curtin.edu.au/genepop/">http://wbiomed.curtin.edu.au/genepop/</ext-link>) to test for Hardy–Weinberg equilibrium.</p>
<p>Association analysis was performed with the core (nuclear) families with one proband (trios). Only one strategy was used – the TDT (available at <ext-link ext-link-type="uri" xlink:href="http://www.jurgott.org/linkage/TDTae.html">http://www.jurgott.org/linkage/TDTae.html</ext-link>) – to avoid the effect of potential population stratification. The statistical significance of differences between clinical features and <italic>DRD2</italic> gene −141C Ins/Del polymorphism in patients was assessed using the χ<sup>2</sup>-test (sex) and two-tailed Student’s <italic>t</italic>-test (age, PANSS scores), accepting <italic>P</italic> &lt; 0.05 as significant.</p>
</sec>
</sec>
<sec id="sec9-0300060513483415" sec-type="results"><title>Results</title>
<p>The study included 120 patients with schizophrenia (55 females/65 males; mean age 44.6 ± 7.3 years) and 100 healthy controls (45 females/55 males, mean age 45.3 ± 5.9 years). The genotype distributions of the <italic>DRD2</italic>−141C Ins/Del polymorphism did not deviate significantly from the Hardy–Weinberg equilibrium in either the patient or the control group (<xref ref-type="table" rid="table1-0300060513483415">Table 1</xref>).
<table-wrap id="table1-0300060513483415" position="float"><label>Table 1.</label><caption><p>Hardy–Weinberg analysis of the −141C insert/delete (I/D) polymorphism in patients with schizophrenia and healthy controls.</p></caption>
<graphic alternate-form-of="table1-0300060513483415" xlink:href="10.1177_0300060513483415-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Group</th>
<th rowspan="2"><italic>n</italic></th>
<th colspan="3">Genotype: <italic>n</italic> (frequency)</th>
<th rowspan="2">χ<sup>2</sup>-value</th>
</tr>
<tr><th>I/I</th>
<th>I/D</th>
<th>D/D</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Patients</td>
<td>120</td>
<td>96 (0.80)</td>
<td>22 (0.18)</td>
<td>2 (0.02)</td>
<td>0.313</td>
</tr>
<tr>
<td>Controls</td>
<td>100</td>
<td>68 (0.68)</td>
<td>28 (0.28)</td>
<td>4 (0.04)</td>
<td>0.265</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>When patients and controls were compared for <italic>DRD2</italic> −141C Ins/Del allele and genotype frequencies, significant (<italic>P</italic> &lt; 0.05) differences were found, with a lower −141C Del frequency observed among 13/120 patients with schizophrenia (11%) compared with 18/100 healthy controls (18%). When patients and control subjects were compared for the <italic>DRD2</italic> −141C D/D genotype, no significant differences were found (<xref ref-type="table" rid="table2-0300060513483415">Table 2</xref>).
<table-wrap id="table2-0300060513483415" position="float"><label>Table 2.</label><caption><p>Allele and genotype frequency comparisons for the <italic>DRD2</italic> −141C insertion/deletion (I/D) polymorphism between patients with schizophrenia and healthy controls.</p></caption>
<graphic alternate-form-of="table2-0300060513483415" xlink:href="10.1177_0300060513483415-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Group</th>
<th rowspan="2"><italic>n</italic></th>
<th colspan="2">Allele: <italic>n</italic> (frequency)</th>
<th rowspan="2">Total</th>
<th colspan="3">Genotype: <italic>n</italic> (frequency)</th>
</tr>
<tr><th>I</th>
<th>D<sup>a</sup></th>
<th>I/I</th>
<th>I/D</th>
<th>D/D<sup>b</sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Patients</td>
<td>120</td>
<td>214 (0.89)</td>
<td>26 (0.11)</td>
<td>240 (1.00)</td>
<td>96 (0.80)</td>
<td>22 (0.18)</td>
<td>2 (0.02)</td>
</tr>
<tr>
<td>Controls</td>
<td>100</td>
<td>164 (0.82)</td>
<td>36 (0.18)</td>
<td>200 (1.00)</td>
<td>68 (0.68)</td>
<td>28 (0.28)</td>
<td>4 (0.04)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513483415"><label>a</label><p>χ<sup><xref ref-type="bibr" rid="bibr2-0300060513483415">2</xref> </sup>= 4.38, df = 1, <italic>P</italic> &lt; 0.05, odds ratio, 0.55, 95% confidence interval, 0.30–0.96. <sup>b</sup>χ<sup>2 </sup>= 4.63, df = 2, not significant.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Linkage relationships were explored in 32 core (nuclear) families. Sixteen parents in these families were −141C Ins/Del heterozygotes. TDT analysis showed that 10 parents transmitted the −141C Ins allele to their offspring and that six transmitted −141C Del to their offspring (difference not significant). Data on the 32 core families failed to demonstrate linkage (<xref ref-type="table" rid="table3-0300060513483415">Table 3</xref>).
<table-wrap id="table3-0300060513483415" position="float"><label>Table 3.</label><caption><p>Transmission disequilibrium test results for the <italic>DRD2</italic> −141C insertion/deletion (I/D) polymorphism in 32 core families (nonschizophrenic parents) of patients with schizophrenia.</p></caption>
<graphic alternate-form-of="table3-0300060513483415" xlink:href="10.1177_0300060513483415-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Transmitted allele</th>
<th colspan="2">No. who transmitted allele</th>
<th>Total</th>
</tr>
<tr><th>I</th>
<th>D</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Ins</td>
<td>14</td>
<td>10</td>
<td>24</td>
</tr>
<tr>
<td>Del</td>
<td>6</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>12</td>
<td>32</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0300060513483415"><label>χ</label><p><sup><xref ref-type="bibr" rid="bibr2-0300060513483415">2</xref> </sup>= 0.71, df = 1, not significant.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Age, age at onset of schizophrenia and sex were not significantly different between −141C Ins and Del patients. Positive symptom score and excitement score were both significantly higher in the Ins than in the Del group (<italic>P</italic> &lt; 0.05 for both scores). The two patient groups did not differ significantly in negative symptom and general psychopathology scores (<xref ref-type="table" rid="table4-0300060513483415">Table 4</xref>).
<table-wrap id="table4-0300060513483415" position="float"><label>Table 4.</label><caption><p>Comparison of clinical features between patients with schizophrenia with one or two C alleles and those with no C allele of the <italic>DRD2</italic> 141C insertion/deletion polymorphism.</p></caption>
<graphic alternate-form-of="table4-0300060513483415" xlink:href="10.1177_0300060513483415-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Clinical feature</th>
<th>One or two C alleles</th>
<th>No C allele</th>
<th>Statistical significance<sup>a</sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex, %</td>
<td>NS</td>
</tr>
<tr>
<td> Male</td>
<td>63.6</td>
<td>42.9</td>
</tr>
<tr>
<td> Female</td>
<td>36.4</td>
<td>57.0</td>
</tr>
<tr>
<td>Age, years</td>
<td>24.1 ± 6.8</td>
<td>31.1 ± 10.9</td>
<td>NS</td>
</tr>
<tr>
<td>PANSS</td>
</tr>
<tr>
<td> Positive symptom score</td>
<td>75.3 ± 23.4</td>
<td>53.9 ± 21.9</td>
<td><italic>P</italic> = 0.010</td>
</tr>
<tr>
<td> Negative symptom score</td>
<td>55.4 ± 16.7</td>
<td>59.1 ± 8.1</td>
<td>NS</td>
</tr>
<tr>
<td> General psychopathology score</td>
<td>70.3 ± 26.9</td>
<td>74.1 ± 31.0</td>
<td>NS</td>
</tr>
<tr>
<td> Excitement score</td>
<td>83.6 ± 16.8</td>
<td>50.3 ± 24.6</td>
<td><italic>P</italic> = 0.018</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0300060513483415"><p>PANSS, Positive and Negative Syndrome Scale; NS, not significant.</p></fn>
<fn id="table-fn4-0300060513483415"><label>a</label><p>Statistical significance determined using χ<sup>2</sup>-test (sex) and two-tailed Student’s <italic>t</italic>-test (age, PANSS score).</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec10-0300060513483415" sec-type="discussion"><title>Discussion</title>
<p>Arinami et al.<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> first reported that −141C Ins/Del may be a functional polymorphism in the 54‐promoter region of <italic>DRD2</italic> and may affect susceptibility to schizophrenia. Their research suggested that the −141C Del allele acts as a protective factor in schizophrenia, while −141C Ins acts as a genetic predisposing factor for the condition. Breen et al.<sup><xref ref-type="bibr" rid="bibr20-0300060513483415">20</xref></sup> found that the −141C Del/Ins polymorphism in the <italic>DRD2</italic> promoter was associated with schizophrenia in the British Caucasian population. This association was the reverse of that found by Arinami et al.<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> A similar study by Lafuente et al.<sup><xref ref-type="bibr" rid="bibr12-0300060513483415">12</xref></sup> showed that the −41C Del allele was significantly more frequent in schizophrenic patients (0.19) than in controls (0.13), in a Spanish population. Hori et al.<sup><xref ref-type="bibr" rid="bibr21-0300060513483415">21</xref></sup> were unable to replicate findings of an association between two functional polymorphisms in the <italic>DRD2</italic> gene and schizophrenia in a Japanese population. As reported by Arinami et al.,<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> the present study findings also indicated a lower frequency of −141C Del among schizophrenic patients (11%) than control subjects (18%). Our findings are the reverse of those of Breen et al.<sup><xref ref-type="bibr" rid="bibr20-0300060513483415">20</xref></sup> in the British Caucasian population and those of Lafuente et al.<sup><xref ref-type="bibr" rid="bibr12-0300060513483415">12</xref></sup> in the Spanish population. Breen et al.<sup><xref ref-type="bibr" rid="bibr20-0300060513483415">20</xref></sup> suggested that linkage disequilibrium, involving different alleles in different ethnic groups, was the most likely explanation for these conflicting findings. Moreover, it is also possible that these polymorphic variants could be in linkage disequilibrium with other gene variants contributing to disease susceptibility, rather than the variant itself being the susceptibility factor. In summary, our study and similar work in a Japanese population<sup><xref ref-type="bibr" rid="bibr21-0300060513483415">21</xref></sup> found lower frequencies of −141C Del among schizophrenic patients than among control subjects, while studies in Caucasian populations showed lower −141C Del frequencies among controls than schizophrenic patients.<sup><xref ref-type="bibr" rid="bibr12-0300060513483415">12</xref>,<xref ref-type="bibr" rid="bibr20-0300060513483415">20</xref></sup> If our findings are correct, this indicated differences between these ethnic groups, which could have important implications for the study of genetic factors.</p>
<p>In the present study, the TDT was performed in 32 nuclear families with one proband (trios), to reduce the rate of type II error (β errors, false negatives). TDT analysis failed to find linkage between schizophrenia and the −141C Ins/Del polymorphism of <italic>DRD2</italic>, which is inconsistent with the case‐control study reported here. Findings of the present study are consistent with some of the results of Lafuente et al.,<sup><xref ref-type="bibr" rid="bibr12-0300060513483415">12</xref></sup> who found no linkage between the −141C Ins/Del polymorphism and the catechol-<italic>O</italic>-methyltransferase polymorphism (A−278 G, G158A), which has been widely studied as a susceptibility gene for the risk of schizophrenia.<sup><xref ref-type="bibr" rid="bibr22-0300060513483415">22</xref><xref ref-type="bibr" rid="bibr23-0300060513483415"/><xref ref-type="bibr" rid="bibr24-0300060513483415"/>–<xref ref-type="bibr" rid="bibr25-0300060513483415">25</xref></sup> In view of the relatively small sample analysed in the present study, replicate studies to evaluate these possibilities are in progress.</p>
<p>Since an association was found in this study between a putative functional promoter polymorphism (−141C Ins/Del) of the <italic>DRD2</italic> gene and schizophrenia, we went further and determined whether there were associations between this polymorphism and clinical features of schizophrenia. There was no significant difference in age and sex between −141C Ins and Del schizophrenia patients, but a higher excitement score was observed in the −141C Ins patient group than in the −141C Del patient group. Excessive activation of D2 receptors in frontal dysfunction has been found to manifest as cognitive difficulties and positive symptoms of schizophrenia.<sup><xref ref-type="bibr" rid="bibr9-0300060513483415">9</xref>,<xref ref-type="bibr" rid="bibr26-0300060513483415">26</xref>,<xref ref-type="bibr" rid="bibr27-0300060513483415">27</xref></sup> Arinami et al.<sup><xref ref-type="bibr" rid="bibr14-0300060513483415">14</xref></sup> concluded that −141C Ins schizophrenia patients had a higher DRD2 concentration and excessive activation of D2 receptors. Our data support this view.</p>
<p>We did not find a linkage relationship between the −141C Ins/Del polymorphism and negative symptoms. This may be explained by a greater number of receptors being involved in negative symptoms, such as the 5-hydroxytryptamine (5-HT, serotonin) receptor, which was not considered in this study.</p>
<p>Compared with other similar studies, careful primer optimization and improved experimental conditions were used here, to provide better-quality experimental results. Two tests were used to reduce the rates of type I errors (false positives) and type II errors (false negatives). However, studies to identify new genetic loci or estimate linkage disequilibrium for loci with multiple alleles in a larger population will be needed, to confirm or exclude allelic susceptibility to schizophrenia in China.</p>
<p>In conclusion, the present and previous results indicate that the <italic>DRD2</italic> gene may be implicated in schizophrenia and that the −141C Del allele acted as a protective factor in schizophrenia, in a Chinese Han population. The Ins allele was associated with positive symptoms (namely, a higher excitement score than that observed in the Del patient group).</p>
</sec>
</body>
<back>
<sec id="sec11-0300060513483415"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec12-0300060513483415"><title>Funding</title>
<p>This work was funded by Natural Science Foundation of Shanghai, China (09ZR1427200).</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513483415"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gejman</surname><given-names>PV</given-names></name><name><surname>Sanders</surname><given-names>A</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name></person-group>. <article-title>The role of genetics in the etiology of schizophrenia</article-title>. <source>Psychiatr Clin North Am</source> <year>2010</year>; <volume>33</volume>: <fpage>35</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr2-0300060513483415"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>JK</given-names></name><name><surname>Malone</surname><given-names>DT</given-names></name><name><surname>Crosby</surname><given-names>IT</given-names></name><etal/></person-group>. <article-title>Schizophrenia: a systematic review of the disease state, current therapeutics and their molecular mechanisms of action</article-title>. <source>Curr Med Chem</source> <year>2011</year>; <volume>18</volume>: <fpage>1380</fpage>–<lpage>1404</lpage>.</citation></ref>
<ref id="bibr3-0300060513483415"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>KC</given-names></name></person-group>. <article-title>The new genetics of schizophrenia</article-title>. <source>Psychiatr Clin North Am</source> <year>2003</year>; <volume>26</volume>: <fpage>41</fpage>–<lpage>63</lpage>.</citation></ref>
<ref id="bibr4-0300060513483415"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>O’Donovan</surname><given-names>MC</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name></person-group>. <article-title>Finding schizophrenia genes</article-title>. <source>J Clin Invest</source> <year>2005</year>; <volume>115</volume>: <fpage>1440</fpage>–<lpage>1448</lpage>.</citation></ref>
<ref id="bibr5-0300060513483415"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaswani</surname><given-names>M</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name></person-group>. <article-title>Genetic basis of schizophrenia: trinucleotide repeats</article-title>. <source>An update. <italic>Prog Neuropsychopharmacol Biol Psychiatry</italic></source> <year>2001</year>; <volume>25</volume>: <fpage>1187</fpage>–<lpage>1201</lpage>.</citation></ref>
<ref id="bibr6-0300060513483415"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Missale</surname><given-names>C</given-names></name><name><surname>Nash</surname><given-names>SR</given-names></name><name><surname>Robinson</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Dopamine receptors: from structure to function</article-title>. <source>Physiol Rev</source> <year>1998</year>; <volume>78</volume>: <fpage>189</fpage>–<lpage>225</lpage>.</citation></ref>
<ref id="bibr7-0300060513483415"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vallone</surname><given-names>D</given-names></name><name><surname>Picetti</surname><given-names>R</given-names></name><name><surname>Borrelli</surname><given-names>E</given-names></name></person-group>. <article-title>Structure and function of dopamine receptors</article-title>. <source>Neurosci Biobehav Rev</source> <year>2000</year>; <volume>24</volume>: <fpage>125</fpage>–<lpage>132</lpage>.</citation></ref>
<ref id="bibr8-0300060513483415"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Forti</surname><given-names>M</given-names></name><name><surname>Lappin</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name></person-group>. <article-title>Risk factors for schizophrenia—all roads lead to dopamine</article-title>. <source>Eur Neuropsychopharmacol</source> <year>2007</year>; <volume>17</volume>: <fpage>S101</fpage>–<lpage>S107</lpage>.</citation></ref>
<ref id="bibr9-0300060513483415"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>RM</given-names></name><name><surname>Lappin</surname><given-names>J</given-names></name><name><surname>Di Forti</surname><given-names>M</given-names></name></person-group>. <article-title>Schizophrenia: from developmental deviance to dopamine dysregulation</article-title>. <source>Eur Neuropsychopharmacol</source> <year>2008</year>; <volume>18</volume>: <fpage>S129</fpage>–<lpage>S134</lpage>.</citation></ref>
<ref id="bibr10-0300060513483415"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Björklund</surname><given-names>A</given-names></name><name><surname>Dunnett</surname><given-names>SB</given-names></name></person-group>. <article-title>Fifty years of dopamine research</article-title>. <source>Trends Neurosci</source> <year>2007</year>; <volume>30</volume>: <fpage>185</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr11-0300060513483415"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sáiz</surname><given-names>PA</given-names></name><name><surname>García-Portilla</surname><given-names>MP</given-names></name><name><surname>Arango</surname><given-names>C</given-names></name></person-group>. <article-title>Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: data from an association study</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <year>2010</year>; <volume>34</volume>: <fpage>26</fpage>–<lpage>31</lpage>.</citation></ref>
<ref id="bibr12-0300060513483415"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lafuente</surname><given-names>A</given-names></name><name><surname>Bernardo</surname><given-names>M</given-names></name><name><surname>Mas</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>−141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population</article-title>. <source>Psychiatr Genet</source> <year>2008</year>; <volume>18</volume>: <fpage>122</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr13-0300060513483415"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bulayeva</surname><given-names>KB</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Bulayev</surname><given-names>OA</given-names></name><etal/></person-group>. <article-title>Genome-wide linkage scan of schizophrenia: a cross-isolate study</article-title>. <source>Genomics</source> <year>2007</year>; <volume>89</volume>: <fpage>167</fpage>–<lpage>177</lpage>.</citation></ref>
<ref id="bibr14-0300060513483415"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name></person-group>. <article-title>A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia</article-title>. <source>Hum Mol Genet</source> <year>1997</year>; <volume>6</volume>: <fpage>577</fpage>–<lpage>582</lpage>.</citation></ref>
<ref id="bibr15-0300060513483415"><label>15</label><citation citation-type="book"><collab>American Psychiatric Association</collab>. <source>Diagnostic and statistical manual of mental disorders</source> <year>2000</year><edition>4th ed</edition>. <publisher-loc>(DSM-IV-TR), Washington DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</citation></ref>
<ref id="bibr16-0300060513483415"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lançon</surname><given-names>C</given-names></name><name><surname>Auquier</surname><given-names>P</given-names></name><name><surname>Nayt</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS)</article-title>. <source>Schizophr Res</source> <year>2000</year>; <volume>42</volume>: <fpage>231</fpage>–<lpage>239</lpage>.</citation></ref>
<ref id="bibr17-0300060513483415"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mass</surname><given-names>R</given-names></name><name><surname>Schoemig</surname><given-names>T</given-names></name><name><surname>Hitschfeld</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale</article-title>. <source>Schizophr Bull</source> <year>2000</year>; <volume>26</volume>: <fpage>167</fpage>–<lpage>177</lpage>.</citation></ref>
<ref id="bibr18-0300060513483415"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marder</surname><given-names>SR</given-names></name><name><surname>Davis</surname><given-names>JM</given-names></name><name><surname>Chouinard</surname><given-names>G</given-names></name></person-group>. <article-title>The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials</article-title>. <source>J Clin Psychiatry</source> <year>1997</year>; <volume>58</volume>: <fpage>538</fpage>–<lpage>546</lpage>.</citation></ref>
<ref id="bibr19-0300060513483415"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mortimer</surname><given-names>AM</given-names></name></person-group>. <article-title>Symptom rating scales and outcome in schizophrenia</article-title>. <source>Br J Psychiatry</source> <year>2007</year>; <volume>191</volume>: <fpage>s7</fpage>–<lpage>s14</lpage>.</citation></ref>
<ref id="bibr20-0300060513483415"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Maude</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>−141C ins/del polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population</article-title>. <source>Am J Med Genet</source> <year>1999</year>; <volume>88</volume>: <fpage>407</fpage>–<lpage>410</lpage>.</citation></ref>
<ref id="bibr21-0300060513483415"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>H</given-names></name><name><surname>Ohmori</surname><given-names>O</given-names></name><name><surname>Shinkai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia</article-title>. <source>Am J Med Genet</source> <year>2001</year>; <volume>105</volume>: <fpage>176</fpage>–<lpage>178</lpage>.</citation></ref>
<ref id="bibr22-0300060513483415"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lafuente</surname><given-names>A</given-names></name><name><surname>Bernardo</surname><given-names>M</given-names></name><name><surname>Mas</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and−141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders</article-title>. <source>Psychiatry Res</source> <year>2008</year>; <volume>161</volume>: <fpage>131</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr23-0300060513483415"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Joo</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans</article-title>. <source>Hum Genet</source> <year>2005</year>; <volume>116</volume>: <fpage>319</fpage>–<lpage>328</lpage>.</citation></ref>
<ref id="bibr24-0300060513483415"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KB</given-names></name><name><surname>Choi</surname><given-names>EH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>The relation of serotonin-related gene and COMT gene polymorphisms with criminal behavior in schizophrenic disorder</article-title>. <source>J Clin Psychiatry</source> <year>2012</year>; <volume>73</volume>: <fpage>159</fpage>–<lpage>163</lpage>.</citation></ref>
<ref id="bibr25-0300060513483415"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutiérrez</surname><given-names>B</given-names></name><name><surname>Rivera</surname><given-names>M</given-names></name><name><surname>Obel</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Variability in the COMT gene and modification of the risk of schizophrenia conferred by cannabis consumption</article-title>. <source>Rev Psiquiatr Salud Ment</source> <year>2009</year>; <volume>2</volume>: <fpage>89</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr26-0300060513483415"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>A</given-names></name></person-group>. <article-title>The dopamine and glutamate theories of schizophrenia: a short review</article-title>. <source>Curr Anaesth Crit Care</source> <year>2009</year>; <volume>20</volume>: <fpage>240</fpage>–<lpage>241</lpage>.</citation></ref>
<ref id="bibr27-0300060513483415"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumperscak</surname><given-names>HG</given-names></name><name><surname>Dolzan</surname><given-names>V</given-names></name><name><surname>Videtic</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Polymorphisms in genes encoding the serotonin and dopamine pathways in two sisters with metachromatic leukodystrophy</article-title>. <source>J Int Med Res</source> <year>2008</year>; <volume>36</volume>: <fpage>1123</fpage>–<lpage>1128</lpage>.</citation></ref>
</ref-list>
</back>
</article>